1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Epigenomics AG

Epigenomics AG

ECX.DE
Epigenomics AGDE flagDeutsche Börse
0.70
EUR
-0.09
- -
612,605.00Market Cap

Total Valuation

Epigenomics AG carries a market capitalization of 612,605.00, placing it among publicly traded companies globally. Its enterprise value stands at 457,610.86, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap612,605.00
Enterprise Value457,610.86

Share Statistics

Epigenomics AG currently has 853,285.00 shares outstanding.

Shares Outstanding853,285.00
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 8.23, and the price-to-book ratio stands at -0.04.

PE RatioN/A
PS Ratio8.23
PB Ratio-0.04
P/TBV Ratio1.99
P/FCF Ratio-0.32
P/OCF Ratio-0.29

Enterprise Valuation

EV / Sales1.02
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Epigenomics AG maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.65, indicating elevated leverage, while an interest coverage ratio of -180.60 demonstrates limited ability to service its debt obligations.

Current Ratio1.93
Quick Ratio1.67
Debt / Equity18.65
Debt / EBITDA-0.02
Interest Coverage-180.60

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-131.18
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.73

Taxes

Income Tax-77,000.00
Effective Tax RateN/A

Stock Price Statistics

Epigenomics AG's stock has declined approximately -82.05128% over the past 52 weeks. The 50-day moving average sits at 1.54, while the 200-day moving average is 2.15.

Beta (5Y)N/A
52-Week Price Change-82.05128%
50-Day Moving Average1.54
200-Day Moving Average2.15
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Epigenomics AG generated 448,000.00 in revenue and converted that into -16.29M in net income, yielding earnings per share of -19.36. EBITDA reached -18.24M, while operating income came in at -18.24M.

Revenue448,000.00
Gross Profit343,000.00
Operating Income-18.24M
Pretax Income-16.37M
Net Income-16.29M
EBITDA-18.24M
EBIT-18.24M
Earnings Per Share (EPS)-19.36

Balance Sheet

Epigenomics AG holds 3.58M in cash and equivalents against 356,000.00 in total debt, resulting in a net debt position of -3.58M. Total book value stands at -100.37M, with working capital of 2.01M providing operational flexibility.

Cash & Cash Equivalents3.58M
Total Debt356,000.00
Net Debt-3.58M
Equity (Book Value)-100.37M
Book Value Per Share-119.28
Working Capital2.01M

Cash Flow

Epigenomics AG produced -12.54M in operating cash flow over the past twelve months. After subtracting -1.03M in capital expenditures, free cash flow totaled -13.57M - equivalent to -16.12 per share.

Operating Cash Flow-12.54M
Capital Expenditures-1.03M
Free Cash Flow-13.57M
FCF Per Share-16.12

Margins

Epigenomics AG operates with a gross margin of 76.56, reflecting its pricing power and cost economics. The operating margin of -4,071.65 and net profit margin of -3,636.16 provide insight into operational efficiency.

Gross Margin76.56
Operating Margin-4,071.65
Pretax Margin-3,653.35
Profit Margin-3,636.16
EBITDA Margin-4,071.65

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield9.85
FCF Yield-312.21

Stock Splits

Epigenomics AG's most recent stock split took place on December 8, 2023 with a 5:1 split ratio.

Last Split Date12/8/2023
Split Ratio5:1

Scores

Epigenomics AG posts an Altman Z-Score of -48.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-48.00